[Featured Stock] Celltrion Applies for European Approval of COVID-19 Treatment...3.55%↑

[Asia Economy Reporter Lee Seon-ae] Celltrion is showing an upward trend in the early trading session following news that it has applied for approval of its COVID-19 treatment (CT-P59) to the US CMP (Committee for Medicinal Products for Human Use under the European Medicines Agency).

As of 9:14 AM on the 25th, Celltrion is trading at 292,000 KRW, up 3.55% from the previous day. At the market open, it rose to 233,500 KRW.

Before the market opened, Celltrion announced, "Based on the secured clinical results, we submitted materials for rolling review yesterday," adding, "We are scheduled to undergo verification and evaluation for approval application by the CHMP (Committee for Medicinal Products for Human Use) under the EMA."

It continued, "We will continue efforts to evaluate and prove the efficacy and safety of CT-P59," and explained, "Based on clinical data, we will proceed with global approvals including Europe and the United States."

This content was produced with the assistance of AI translation services.